Allogeneic stem cell transplantation in chronic myeloid leukaemia - 2 1/2 Year experience

Journal of the Pakistan Medical Association

Volumn 55, Issue 11, 2005, Pages 478-482

  Hashmi, KhalilUllah ^a   Khan, Badshah ^a   Ahmed, Parvez ^a   Hussain, Iftikhar ^b   Raza, Shahid ^a   Iqbal, Hamid ^a   Malik, Hamid Saeed ^a   Kamal, Muhammad Khalid ^a   Anwar, Masood ^a  

^a National University of Medical Sciences   (Pakistan)

^b Peshawar Cantonment   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE; PREDNISOLONE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HOSPITALIZATION; HUMAN; INFECTION; MALE; MORTALITY; NEUTROPHIL COUNT; PLEURA EFFUSION; SEPTICEMIA; THROMBOCYTE COUNT; TREATMENT OUTCOME; TUBERCULOSIS; VEIN OCCLUSION; ADOLESCENT; ALLOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; MIDDLE AGED; PRESCHOOL CHILD; PROSPECTIVE STUDY; PUBLIC HOSPITAL; RISK ASSESSMENT; SIBLING; SURVIVAL;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; HOSPITALS, MILITARY; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; SIBLINGS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33644795070     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Appelbaum FR. Allogeneic transplantation for Chronic Myeloid Leukaemia, Blume KG, forman SJ, Appelbaum FR (eds): in Thomas haematopoietic cell transplantation, Massachusetts, Blackwell Publishing Ltd 2004;1007-17.
2. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukaemia Blood 2000;96:3343-56.
3. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000 CA cancer J Clin 2000;50:7-33.
4. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al. Randomized comparison of busulphan and hydroxyurea in Chronic Myelogenous Leukaemia: prolongation of survival by hydroxyurea. Blood 1993;82:398-407.
5. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al. Randomized Comparison of interferon- with busulphan and hydroxyurea in chronic myelogenous leukaemia. Blood 1994;84:4064-77.
6. Hughes TP, Kaeda J, Brandford S, Rudzki Z, Hochhaus A, Hensley ML, et al. For the international Randomized study of Interferon versus STI-571 (IRIS Study Group). Frequency of major molecular responses to imatinib or interferon alfa + cyiarabin in newly diagnosed chronic myeloid leukaemia. N Engl J Med 2003;349:1423-32.
7. Peggs K, Mackinnon S. Imaitinb mesylate - the new gold, standard for treatment of chronic myeloid leukemia. Eng J Med 2003;348:1848-50.
8. Goldman JM, Druker BJ. Chronic myeloid leukaemia, current treatment options Blood 2001;98:2039-42.
9. Clift RA, Buckner CD, Thomas ED, Doney K, Fefer A, Neiman PE, et al. Treatment of chronic granulocytic leukaemia in Chronic phase by allogeneic marrow transplantation. Lancet 1982;2:621-3.
10. Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WT, et al. Marrow transplantation for the treatment of chronic myelogenous leukaemia. Ann intern Med 1986;104:155-63.
11. International Bone marrow transplant registry. http://www.ibmtr.org.2002.
12. Radich JP, Gooley T, Bensinger W, Chauncey T, Clift R, Flowers M, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003;102:31-5.
13. Link H, Bohme A, Cornely OA, Hofften K, Kellner O, Kern WV, et al. Antimicrobial therapy infectious diseases working party (AGIHO) of German Society of Haematology and Oncology (OGHO), study group interventional therapy of unexplained fever, Arbeitsgmein schaft supportivema ssnahmen in det OnKologic (ASO of deutsche Krebsgesellschaft (DKG-German Cancer Society) Ann Hematol 2003;52(suppl 2):105-17.
14. Rowe JM, Ciobanu N, Ascensao J, Stadtmauer EA, Weiner RS, Schenkein DP, et al. Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. Ann Intern Med 1994;120:143-58.
15. Maness LJ, Mc Sweeney PA. Treatment options for newly diagnosed patients with chronic myeloid leukemia. Curr Hematol Rep 2004;3:54-61.
16. Schmitz N, Bacigalupo A, Iabopin M, Majolino L, Laporte JP, Brinch I, et al. Transplantation of peripheral blood progenitor cells from HLA identical sibling donors. European Group for Blood and marrow transplantation (EBMT) Br J Haematol 1996;95:715-23.
17. Baglin TP. Veno-occlusive disease of the liver complicating bone marrow transplantation. Bone Marrow Transplant 1994;13:1-4.
18. Shulman HM, Hinterberger W. Hepatic veno-occlusive disease-liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992;10:197-214.
19. Meisenberg B, M. Lassiter M, Hussein A, Ross M, Vredenburgh JJ, Peters WP. Prevention of hemorrhagic eyelids after high-dose alkylating agent chemotherapy and autologous bone marrow support. Bone Marrow Transplant 1994;14:287-91.
20. Wingard JR. Advances in the management of infectious complications after bone marrow transplantation. Bone Marrow Transplant 1990;6:371-83.
21. Hoyle C, Goldman JM. Life-threatening infections occurring more than 3 months after BMT. Bone Marrow Transplant 1994;14:247-52.
22. Fang Y, Gratwohi A, van Houwelingen HC. Relapse risk assessment of transplantation for patients with chronic myeloid leukaemia Chin Med J (Engl) 2003;116:305-8.
23. Millot F, Esperou H, Bordigoni P, Dalle JH, Michailet M, Michel G, et al. Allogeneic bone marrow transplantation for chronic myeloid leukaemia in childhood: a report from the societe Francaise de Greffe de moelle et de therapeutic cellulaire 9SFGM-TC). Bone Marrow Transplant 2003;32:993-9.
24. Devries CR, Freiha FS. Hemorrhagic Cystitis. J Urol 1990;143:1-9.
25. Shamsi TS, Irfan M, Ansari SH, Farzana T, Khalid MT, Panjwani VK, et al. Allogeneic peripheral blood stem cell transplantation in patients with Haematological malignancies J Coll Physicians Surg Pak 2004;14:522-6.